Radiopharm Theranostics (RADX) said its DSMC recommended advancing 177Lu-RAD202 to Cohort 4 at a higher dose level of 180mCi in the Phase 1 HEAT trial. This is a positive clinical progression step, implying tolerance/monitoring support for escalation. Likely modest impact given it is an early-stage trial update.
Radiopharm Theranostics (RADX) said its DSMC recommended advancing 177Lu-RAD202 to Cohort 4 at a higher dose level of 180mCi in the Phase 1 HEAT trial. This is a positive clinical progression step, implying tolerance/monitoring support for escalation. Likely modest impact given it is an early-stage trial update.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request DemoOverall Sentiment
mildly positive
Sentiment Score
0.25
Ticker Sentiment
